Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 34 (22) 2602-2609
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
2267  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Roche/Genentech, Novartis  
Grants:
U10CA180821, U10CA180882, U10CA180863, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA180858, U10 CA180795, P30 CA008748, U10 CA180791, U10 CA180882, U10 CA180820, U10 CA180867, U10 CA180838, U10 CA180888, U10 CA138561  
Corr. Author:
 
Authors:
                               
Networks:
CA136, LAPS-CT018, LAPS-IL057, LAPS-NC007, LAPS-NY016, LAPS-TX035, NY018, TX041   
Study
CALGB-40503
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Bc7, ORIGINAL REPORTS, Breast Cancer